BIOCRYST PHARMACEUTICALS, INC. (BCRX) Debt Components
- 2026-06-30: Long-term Debt, Excluding Current MaturitiesUSD $395.40M; Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m); Long-term DebtUSD (m).
- 2026-03-31: Long-term Debt, Excluding Current MaturitiesUSD $395.20M; Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m); Long-term DebtUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD $0.00; Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m); Long-term DebtUSD (m).
- 2025-09-30: Long-term Debt, Excluding Current MaturitiesUSD $194.37M; Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m); Long-term DebtUSD (m).
BIOCRYST PHARMACEUTICALS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Notes Payable, Current USD | Long-term Line of Credit USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $395.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $395.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $194.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $242.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $315.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $314.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $314.33M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $313.82M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $308.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $303.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $298.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $293.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $232.52M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $11.93M |
| 2022-12-31 | $231.62M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $223.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $12.51M |
| 2022-06-30 | $144.52M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $140.24M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | $298.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $136.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $132.05M | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $126.80M | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $123.04M | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | $122.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $119.73M | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $29.89M | $26.89M | $45.00M | $20.00M | $20.00M | (m) | (m) | (m) | $5.00M | (m) |
| 2020-06-30 | (m) | $29.78M | $31.71M | $50.00M | $20.00M | $20.00M | (m) | (m) | (m) | $10.00M | (m) |
| 2020-03-31 | (m) | $29.67M | $36.51M | $50.00M | (m) | $20.00M | $20.00M | (m) | (m) | $10.00M | (m) |
| 2019-12-31 | $0.00 | $29.56M | $41.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | $50.00M | $10.00M | $20.00M | $20.00M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $29.45M | $46.04M | $50.00M | (m) | $10.00M | $20.00M | $20.00M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $29.34M | $49.85M | $50.00M | (m) | $10.00M | $20.00M | $20.00M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $29.23M | $49.62M | $50.00M | (m) | $10.00M | $20.00M | $20.00M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $29.12M | $25.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | $30.00M | $5.00M | $12.00M | $12.00M | $1.00M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $29.01M | $28.29M | $30.00M | (m) | $5.00M | $12.00M | $12.00M | $1.00M | (m) | (m) |
| 2018-06-30 | (m) | $28.90M | $13.47M | $19.55M | (m) | $6.90M | $6.90M | $2.30M | (m) | $3.45M | (m) |
| 2018-03-31 | (m) | $28.79M | $15.11M | $21.27M | (m) | $6.90M | $6.90M | $2.30M | (m) | $5.17M | (m) |
| 2017-12-31 | (m) | $28.68M | $16.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | $23.00M | (m) | $6.90M | $6.90M | $6.90M | $2.30M | (m) | (m) |
| 2017-09-30 | (m) | $28.57M | $18.38M | $23.00M | (m) | $6.90M | $6.90M | $6.90M | $2.30M | (m) | (m) |
| 2017-06-30 | (m) | $28.46M | $20.00M | $23.00M | (m) | $6.90M | $6.90M | $6.90M | $2.30M | (m) | (m) |
| 2017-03-31 | (m) | $28.35M | $21.61M | $23.00M | (m) | $6.90M | $6.90M | $6.90M | $2.30M | (m) | (m) |
| 2016-12-31 | (m) | $28.24M | $22.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | $23.00M | (m) | $6.90M | $6.90M | $6.90M | $2.30M | (m) | (m) |
| 2016-09-30 | (m) | $28.13M | $22.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $28.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $27.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $27.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |